Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.

Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to license the therapy for further development and commercialization, resulting in a milestone payment to Quell of $10 million.

While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of research excluding women from clinical trials and investment decisions.